logo
Plus   Neg
Share
Email

Sandoz Resubmits BLA For Proposed Biosimilar Pegfilgrastim To FDA - Quick Facts

Sandoz, a Novartis division, announced resubmission of its Biologics License Application (BLA) for a proposed biosimilar pegfilgrastim to the US FDA to address an FDA complete response letter received in June 2016. The resubmission includes new data from a pivotal pharmacokinetics and pharmacodynamics study.

Sandoz said it is pursuing approval of biosimilar pegfilgrastim to decrease the incidence of infection, as manifested by febrile neutropenia (low white blood cell count with a fever), in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. The company said the new data was from a single-dose, three-period cross-over study comparing Sandoz pegfilgrastim with US-sourced reference pegfilgrastim; Sandoz pegfilgrastim with EU-sourced reference pegfilgrastim; and US with EU-sourced reference pegfilgrastim.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fiat Chrysler Automobiles N.V. (FCAU) has submitted a 50/50 merger proposal to the Board of Groupe Renault (RNSDY.PK, RNSDF.PK, RNT.L). Under the proposal, the combined company would be owned 50% by FCA shareholders and 50% by Groupe Renault shareholders. Separately, Groupe Renault confirmed it has received... Alibaba is upgrading its intellectual property system using blockchain technology, according to local news outlet Sohu. Alibaba Platform Management expects this to benefit mainly small and medium-sized enterprises, brands and entrepreneurs. The technology will be fully implemented in September, and thereafter, the company intends to expand it to the field of digital copyright protection. Electronics retailer Best Buy Co., Inc. (BBY) reported Thursday a 27 percent increase in profit for the first quarter from last year, which was impacted by restructuring charges, and higher revenues. Both adjusted earnings per share and revenues for the quarter topped analysts' estimates. The company also provides guidance for the second quarter and reiterated its outlook for the full-year 2020.
Follow RTT